A 52-year-old woman with HER2-positive metastatic breast cancer is initiated on trastuzumab (Herceptin). Which is the most common cardiac adverse effect associated with this monoclonal antibody?

Explanation

## Trastuzumab-Induced Cardiotoxicity ### Mechanism of HER2 Inhibition and Cardiac Toxicity Trastuzumab is a recombinant humanized monoclonal antibody against HER2 (human epidermal growth factor receptor 2). HER2 is expressed on cardiac myocytes and is crucial for cardioprotection and cellular survival. Trastuzumab binding blocks HER2 signaling, leading to loss of cardioprotective signals and myocyte apoptosis. **Key Point:** Trastuzumab-induced cardiotoxicity manifests primarily as **dilated cardiomyopathy with reduced ejection fraction (HF-rEF)**, NOT acute ischemic events or arrhythmias. ### Incidence and Clinical Features | Feature | Details | |---------|----------| | **Incidence** | 5–10% symptomatic; 20–30% asymptomatic LVEF decline | | **Onset** | Usually within first year of therapy; can occur years later | | **Presentation** | Dyspnea, fatigue, orthopnea, peripheral edema (HF symptoms) | | **LVEF decline** | ≥10% absolute decline or LVEF <50% | | **Reversibility** | Partially reversible with ACE inhibitors, beta-blockers, diuretics | | **Risk factors** | Age >50, prior anthracycline, baseline LVEF <55%, hypertension | ### Pathophysiology 1. HER2 inhibition → loss of PI3K/Akt and MAPK survival signaling 2. Increased myocyte apoptosis and oxidative stress 3. Mitochondrial dysfunction and energy depletion 4. Progressive myocardial remodeling → dilated cardiomyopathy 5. Reduced contractility and ejection fraction ### Monitoring and Management ```mermaid flowchart TD A[Baseline LVEF assessment]:::action --> B{LVEF <50% or <40% decline?}:::decision B -->|No| C[Continue trastuzumab + repeat ECHO q3 months]:::action B -->|Yes| D[Hold trastuzumab]:::urgent D --> E[Start cardioprotective therapy]:::action E --> F[ACE-I/ARB + Beta-blocker]:::action F --> G{LVEF recovery?}:::decision G -->|Yes| H[Resume trastuzumab with cardio monitoring]:::action G -->|No| I[Consider permanent discontinuation]:::urgent ``` **Clinical Pearl:** Baseline LVEF assessment (echocardiography or MUGA scan) is mandatory before trastuzumab initiation. Serial monitoring every 3 months during therapy and 6–12 months post-therapy is standard practice. **High-Yield:** Trastuzumab cardiotoxicity is **dose-independent** and **cumulative**, unlike anthracycline cardiotoxicity. It can occur even after therapy completion. Concurrent anthracycline use significantly increases risk. **Mnemonic:** **HER2 Cardiotoxicity = Dilated Cardiomyopathy (HF-rEF)** - **H**ER2 inhibition → **E**jection fraction **R**eduction - **2** pathways: apoptosis + oxidative stress ### Why NOT Other Options? - **Acute MI:** Trastuzumab does not cause coronary vasospasm or thrombosis; acute MI is not a recognized cardiotoxicity pattern. - **Pericardial effusion:** Not a typical manifestation; occurs in malignancy-related pericarditis, not HER2 inhibition. - **Atrial fibrillation:** Not a primary trastuzumab effect; arrhythmias are secondary to HF, not direct drug toxicity.